236 related articles for article (PubMed ID: 25970777)
1. c-Jun N-terminal kinase 2 prevents luminal cell commitment in normal mammary glands and tumors by inhibiting p53/Notch1 and breast cancer gene 1 expression.
Cantrell MA; Ebelt ND; Pfefferle AD; Perou CM; Van Den Berg CL
Oncotarget; 2015 May; 6(14):11863-81. PubMed ID: 25970777
[TBL] [Abstract][Full Text] [Related]
2. Jnk2 effects on tumor development, genetic instability and replicative stress in an oncogene-driven mouse mammary tumor model.
Chen P; O'Neal JF; Ebelt ND; Cantrell MA; Mitra S; Nasrazadani A; Vandenbroek TL; Heasley LE; Van Den Berg CL
PLoS One; 2010 May; 5(5):e10443. PubMed ID: 20454618
[TBL] [Abstract][Full Text] [Related]
3. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
[TBL] [Abstract][Full Text] [Related]
4. A mouse model for luminal epithelial like ER positive subtype of human breast cancer.
Kumar MJ; Ponvijay KS; Nandhini R; Nagarajan RS; Jose J; Srinivas G; Nagarajan P; Venkatesan R; Kumar K; Singh S
BMC Cancer; 2007 Sep; 7():180. PubMed ID: 17880731
[TBL] [Abstract][Full Text] [Related]
5. Multipotent luminal mammary cancer stem cells model tumor heterogeneity.
Bao L; Cardiff RD; Steinbach P; Messer KS; Ellies LG
Breast Cancer Res; 2015 Oct; 17(1):137. PubMed ID: 26467658
[TBL] [Abstract][Full Text] [Related]
6. JNK2 downregulation promotes tumorigenesis and chemoresistance by decreasing p53 stability in bladder cancer.
Pan CW; Liu H; Zhao Y; Qian C; Wang L; Qi J
Oncotarget; 2016 Jun; 7(23):35119-31. PubMed ID: 27147566
[TBL] [Abstract][Full Text] [Related]
7. Notch1-induced mammary tumor development is cyclin D1-dependent and correlates with expansion of pre-malignant multipotent duct-limited progenitors.
Ling H; Sylvestre JR; Jolicoeur P
Oncogene; 2010 Aug; 29(32):4543-54. PubMed ID: 20562911
[TBL] [Abstract][Full Text] [Related]
8. c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer.
Regan JL; Kendrick H; Magnay FA; Vafaizadeh V; Groner B; Smalley MJ
Oncogene; 2012 Feb; 31(7):869-83. PubMed ID: 21765473
[TBL] [Abstract][Full Text] [Related]
9. Role of JNK in a Trp53-dependent mouse model of breast cancer.
Cellurale C; Weston CR; Reilly J; Garlick DS; Jerry DJ; Sluss HK; Davis RJ
PLoS One; 2010 Aug; 5(8):e12469. PubMed ID: 20814571
[TBL] [Abstract][Full Text] [Related]
10. Alpha-6 integrin deletion delays the formation of Brca1/p53-deficient basal-like breast tumors by restricting luminal progenitor cell expansion.
Faraldo MM; Romagnoli M; Wallon L; Dubus P; Deugnier MA; Fre S
Breast Cancer Res; 2024 Jun; 26(1):91. PubMed ID: 38835038
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms and protein expression of P53 and BRCA1 in preneoplastic and neoplastic rat mammary glands.
Al-Dhaheri W; Hassouna I; Karam SM
Oncol Rep; 2018 May; 39(5):2193-2200. PubMed ID: 29498408
[TBL] [Abstract][Full Text] [Related]
12. c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun.
Xie X; Kaoud TS; Edupuganti R; Zhang T; Kogawa T; Zhao Y; Chauhan GB; Giannoukos DN; Qi Y; Tripathy D; Wang J; Gray NS; Dalby KN; Bartholomeusz C; Ueno NT
Oncogene; 2017 May; 36(18):2599-2608. PubMed ID: 27941886
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway.
Akli S; Van Pelt CS; Bui T; Multani AS; Chang S; Johnson D; Tucker S; Keyomarsi K
Cancer Res; 2007 Aug; 67(15):7212-22. PubMed ID: 17671189
[TBL] [Abstract][Full Text] [Related]
14. Pathways contributing to development of spontaneous mammary tumors in BALB/c-Trp53+/- mice.
Yan H; Blackburn AC; McLary SC; Tao L; Roberts AL; Xavier EA; Dickinson ES; Seo JH; Arenas RB; Otis CN; Cao QJ; Lawlor RG; Osborne BA; Kittrell FS; Medina D; Jerry DJ
Am J Pathol; 2010 Mar; 176(3):1421-32. PubMed ID: 20110418
[TBL] [Abstract][Full Text] [Related]
15. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
Cicchini M; Chakrabarti R; Kongara S; Price S; Nahar R; Lozy F; Zhong H; Vazquez A; Kang Y; Karantza V
Autophagy; 2014; 10(11):2036-52. PubMed ID: 25483966
[TBL] [Abstract][Full Text] [Related]
16. c-Jun N-terminal kinase 2 (JNK2) enhances cell migration through epidermal growth factor substrate 8 (EPS8).
Mitra S; Lee JS; Cantrell M; Van den Berg CL
J Biol Chem; 2011 Apr; 286(17):15287-97. PubMed ID: 21357683
[TBL] [Abstract][Full Text] [Related]
17. The histone methyltransferase EZH2 promotes mammary stem and luminal progenitor cell expansion, metastasis and inhibits estrogen receptor-positive cellular differentiation in a model of basal breast cancer.
Wu J; Crowe DL
Oncol Rep; 2015 Jul; 34(1):455-60. PubMed ID: 25998860
[TBL] [Abstract][Full Text] [Related]
18. Transformation of enriched mammary cell populations with polyomavirus middle T antigen influences tumor subtype and metastatic potential.
Drobysheva D; Smith BA; McDowell M; Guillen KP; Ekiz HA; Welm BE
Breast Cancer Res; 2015 Oct; 17(1):132. PubMed ID: 26429062
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells.
Cotrim CZ; Fabris V; Doria ML; Lindberg K; Gustafsson JÅ; Amado F; Lanari C; Helguero LA
Oncogene; 2013 May; 32(19):2390-402. PubMed ID: 22751110
[TBL] [Abstract][Full Text] [Related]
20. Humanization of the mouse mammary gland by replacement of the luminal layer with genetically engineered preneoplastic human cells.
Verbeke S; Richard E; Monceau E; Schmidt X; Rousseau B; Velasco V; Bernard D; Bonnefoi H; MacGrogan G; Iggo RD
Breast Cancer Res; 2014 Dec; 16(6):504. PubMed ID: 25527189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
